Alzheimer’s & Dementia
News
Warnings and Advisories Issued to 17 Companies for Products Illegally Marketed as Treatment for Alzheimer’s Disease
Tuesday, February 12, 2019—The Food and Drug Administration (FDA) posted 12 warning letters and 5 online advisory letters issued to 17 foreign and domestic companies that illegally sell more than 58 pro…
Study Shows That Learning Processes May Determine Severity of PTSD Symptoms
Friday, February 08, 2019—Findings from a study published in Nature Neurosciencereveal distinct patterns for how the brain and body respond when learning about danger and safety. The findings coul…
Level of Education Shown Not to Correlate to Rate of Cognitive Decline in Those With or Without Dementia
Thursday, February 07, 2019—Some studies have suggested that a higher level of education may correlate with lower incidence of dementia, which has been interpreted as suggesting education could increase …
Tau Pathology of Alzheimer’s Linked to Sleep-Wake Cycle
Wednesday, February 06, 2019—Poor sleep is a symptom of Alzheimer’s disease (AD) that worsens as the disease progresses and is also suggested to be an early symptom of AD. It has been known for some…
Genentech Discontinuing Phase 3 Clinical Studies of Crenezumab for Early Alzheimer’s Disease
Thursday, January 31, 2019—The phase 3 studies, CREAD 1 (NCT02670083) and CREAD 2 (NCT03114657), of crenezumab (Genetech, South San Francisco, CA), an investigational monoclonal antibody to am…
FDA Grants Breakthrough Device Designation for Alzheimer’s Disease Screening Test
Wednesday, January 30, 2019—The Food and Drug Administration (FDA) has granted Breakthrough Device Designation for a brain amyloidosis blood test (C2N Diagnostics, St. Louis, MO) that screens patien…
Leaky Blood-Brain Barrier May Be Early Biomarker for Cognitive Dysfunction
Monday, January 21, 2019—In a study published in the journal Nature Medicine, researchers showed a correlation between damage of capillaries in the hippocampal region and early cognitive dys…
First Patient Enrolled in Phase 3 Trial of Low-Dose Formulation of Levetiracetam for Mild Cognitive Impairment
Thursday, January 17, 2019—A first patient has been enrolled in a phase 3 clinical trial of a proprietary low-dose formulation of the antiepileptic drug levetiracetam (AGB101; AgeneBio, Baltimore,MD) fo…
